{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '10.3.5.', 'Reporting of SAEs', 'SAE Reporting to the Sponsor via an Electronic Data Collection Tool', 'The mechanism for reporting an SAE to the Sponsor will be the electronic data capture system.', 'If the electronic system is unavailable, then the site will contact the Medical Monitor in order', 'to report the event and submit the paper SAE report form via the contacts below within 24', 'hours.', 'The site will enter the SAE data into the electronic system as soon as it becomes available.', 'After the study is completed at a given site, the electronic data collection tool will be taken off-', 'line to prevent the entry of new data or changes to existing data.', 'If a site receives a report of a new SAE from a study subject or receives updated data on a', 'previously reported SAE after the electronic data collection tool has been taken off-line, then', 'the site can report this information via contact to the Medical Monitor and submitting the paper', 'SAE report form via the contacts below.', 'Contacts for SAE reporting can be found below.', '59', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '10.4.', 'Appendix 4: Contraceptive Guidance and Collection of Pregnancy', 'Information', 'Definitions:', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal unless', 'permanently sterile (see below).', 'If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be', 'confirmed before first dose of IP, additional evaluation should be considered.', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2. Premenopausal female with 1 of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', 'For individuals with permanent infertility due to an alternate medical cause other than the', 'above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be', 'applied to determining study entry.', \"Note: Documentation can come from the site personnel's: review of the subject's medical\", 'records, medical examination, or medical history interview.', '3. Postmenopausal female', 'A postmenopausal state is defined as no menses for 12 months without an alternative', 'medical cause.', '- A high follicle stimulating hormone (FSH) level (eg, > 40 IU/L) in the', 'postmenopausal range may be used to confirm a postmenopausal state in women', 'not using hormonal contraception or hormonal replacement therapy (HRT).', 'However, in the absence of 12 months of amenorrhea, confirmation with more', 'than one FSH measurement is required.', 'Females on HRT and whose menopausal status is in doubt will be required to use one', 'of the non-estrogen hormonal highly effective contraception methods if they wish to', 'continue their HRT during the study. Otherwise, they must discontinue HRT to allow', 'confirmation of postmenopausal status before study enrollment.', '60', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Contraception Guidance:', 'A female subject is eligible to participate if she is not pregnant or breastfeeding,', 'and at least one of the following conditions applies:', '-', 'Is not a woman of childbearing potential (WOCBP)', 'OR', '-', 'Is a WOCBP and using a contraceptive method that is highly effective', '(with a failure rate of < 1% per year), preferably with low user dependency', '(see table below), at least 1 month prior to Screening, during the intervention', 'period, and for 28 days after the last dose of IP, and agrees not to donate leggs', '(ova, oocytes) for the purpose of reproduction during this period. The investigator', 'should evaluate the effectiveness of the contraceptive method in relationship to', 'the first dose of IP.', '-', 'A WOCBP must have a negative highly sensitive pregnancy test (urine or serum', 'as required by local regulations) within 24 hours before the first dose of IP.', '- If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum', 'pregnancy test is required. In such cases, the subject must be excluded from', 'participation if the serum pregnancy result is positive.', 'Contraceptive use should be consistent with local regulations regarding the use of contraceptive', 'methods for those participating in clinical studies.', '61', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}